Palbociclib

Department of Health written question – answered at on 22 February 2017.

Alert me about debates like this

Photo of Mary Glindon Mary Glindon Shadow Minister (Environment, Food and Rural Affairs) (Farming and Rural Communities)

To ask the Secretary of State for Health, what discussions he has had with charities on the future of the drug palbociclib (Ibrance).

Photo of Siobhain McDonagh Siobhain McDonagh Labour, Mitcham and Morden

To ask the Secretary of State for Health, what recent discussions he has had with metastatic breast cancer patients on the future availability of the Ibrance form of the drug palbociclib.

Photo of Nicola Blackwood Nicola Blackwood The Parliamentary Under-Secretary of State for Health

Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides independent, evidence-based guidance for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE is currently appraising palbociclib in combination with an aromatase inhibitor for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer in adults. NICE published its draft guidance on 3 February and stakeholders have until 24 February to comment on its draft recommendations. NICE expects to publish its final guidance in June 2017.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.